发布文献求助

科研小白

Lv52

810 积分 2025-04-18 加入

最近求助
最近应助
互助留言

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data 6天前 已完结
Replacing cholesterol in liposomes by an Astragaloside IV derivative prolongs the circulation time and improves drug delivery to the fibrotic heart 15天前 已完结
Replacing cholesterol in liposomes by an Astragaloside IV derivative prolongs the circulation time and improves drug delivery to the fibrotic heart 15天前 已完结
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia 21天前 已关闭
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia 21天前 已关闭
Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma 21天前 已关闭
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma 21天前 已关闭
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies 21天前 已关闭
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) 21天前 已关闭
Anti-CD33 Antibody-Drug Conjugate (Gemtuzumab ozogamicin) in Adult Acute Myeloid Leukemia: Real Life Data from Iraq 21天前 已完结

没有进行任何应助

最近帖子
最近评论

没有发布任何帖子

没有发布任何评论

Copyright © 2020-2026 AbleSci.COM, 科研通, All Right Reserved

科研通是非营利科研互助平台，不忘初心，为科研助力

本站互助的所有文件仅供个人学习研究用，禁止任何人把求助的所得文献进行盈利或传播

皖ICP备2024041134号-1

皖公网安备34019202002308

科研通【文献互助QQ群】：如果您有特殊求助，或发布求助超过24小时未得到应助，可加群求助，群号：821889395【点击一键加群】

科研通【志愿服务QQ群】：如果您热爱文献互助，有热心愿意为更多人服务，请加入小伙伴群，点击申请加入

关注微信服务号

科研通